Efferon wants to eradicate the devastating toll of pediatric sepsis; plus, Petra Power looks to modernize energy for data centers

This is TechCrunch. This episode is brought to you by Framer. You know what's absolutely terrifying? A bad website. Or worse, one that doesn't work. Avoid that nightmare and use Framer. Framer is the AI website builder that helps creators, teams, and businesses ship production-ready sites faster than ever while getting every detail right. Prompt, inspect, edit, and publish in one place at a whole new pace. So I was new to this whole website building thing, but Framer helped me get set up and running incredibly fast. For instance, I wanted to add a blog to my website. It was super easy. Starting with a basic blog page template, I added some breakpoints and then jumped into customizing my layout, adding my own special touches with Framer's intuitive tools, and bam! I was ready to start letting my thoughts flow. See why thousands are trusting Framer to help build their websites. Learn how you can get more out of your site from a Framer specialist or get started building for free today at framer.com slash tcstartups for 30% off a Framer Pro annual plan. That's framer.com slash tcstartups. Rules and restrictions may apply. Sepsis is an acute inflammation triggered by infection, and it is a leading cause of childhood mortality, claiming roughly 3 million children under the age of 5 annually. Everon, a startup selected as one of TechCrunch Disrupt's 2026's Startup Battlefield 200, is on a mission to drastically lower that number. The company has developed a medical device that it says lowers organ failure rates and significantly accelerates recovery in children. When standard treatments like antibiotics cannot stop the immune system's overreaction, a patient's blood must be filtered to remove deadly toxins. That is where Efferon's devices of absorbers of dangerous cytokines and toxins step in to make a critical difference. Dima Romashin. Efiron's co-founder and CEO compares what happens in the body during sepsis to a fire, where an immune response overwhelms the body rapidly. In sepsis, endotoxins are the flames and cytokines are the smoke. Efiron, unlike other devices on the market, has developed a mechanism that can absorb both at once. Although Efiron makes absorbers for adults, Efiron Neo, its pediatric device developed specifically for young kids, is proving especially effective. Since children have a significantly lower circulating blood volume, they require medical devices engineered specifically for their physiology. In April, Ephiron Neo received a CE mark, Europe's equivalent to FDA approval, making it the first multimodal blood purification device specifically engineered for pediatric sepsis. Ephiron Neo is used in intensive care units across 30 countries, including European hospitals, Saudi Arabia, and Thailand. The company is now preparing to file for FDA approval. and is on track to hit $2 million in annualized revenue by the end of this year. The startup's technology was originally developed by scientists at Moscow State University, including co-founder Ivan Besinov. Recognizing its potential, Romashin, a serial entrepreneur, stepped in earlier this year as CEO to help commercialize it. Although Romeshin admits that Eferon is not